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ART ICLE Open Ac ce s s
Global alteration of T-lymphocyte metabolism by
PD-L1 checkpoint involves a block of de novo
nucleoside phosphate synthesis
Nicolaos Jay Palaskas1,2, Jacob David Garcia3, Roksana Shirazi4, Daniel Sanghoon Shin1,2, Cristina Puig-Saus1,
Daniel Braas2,5,6, Antoni Ribas 1,2,7,8,9 and Thomas Glen Graeber 2,5,6,7,8
Abstract
Metabolic obstacles of the tumor microenvironment remain a challenge to T-cell-mediated cancer immunotherapies.
To better understand the interplay of immune checkpoint signaling and immune metabolism, this study developed
and used an optimized metabolite extraction protocol for non-adherent primary human T-cells, to broadly profile
in vitro metabolic changes effected by PD-1 signaling by mass spectrometry-based metabolomics and isotopomer
analysis. Inhibitory signaling reduced aerobic glycolysis and glutaminolysis. A general scarcity across the panel of
metabolites measured supported widespread metabolic regulation by PD-1. Glucose carbon fate analysis supported
tricarboxylic acid cycle reliance on pyruvate carboxylation, catabolic-state fluxes into acetyl-CoA and succinyl-CoA, and
a block in de novo nucleoside phosphate synthesis that was accompanied by reduced mTORC1 signaling.
Nonetheless, exogenous administration of nucleosides was not sufficient to ameliorate proliferation of T-cells in the
context of multiple metabolic insufficiencies due to PD-L1 treatment. Carbon fate analysis did not support the use of
primarily glucose-derived carbons to fuel fatty acid beta oxidation, in contrast to reports on T-memory cells. These
findings add to our understanding of metabolic dysregulation by PD-1 signaling and inform the effort to rationally
develop metabolic interventions coupled with immune-checkpoint blockade for increased treatment efficacy.
Introduction
Immune-checkpoint blockade targeting programmed
cell death 1 (PDCD1/PD-1) and its ligand CD274 (PD-L1)
has shown promise for the treatment of tumors of various
histologies, with long-term responses and limited toxi-
cities in a subset of patients1. T-cells found at the tumor
margin can infiltrate and proliferate within the tumor
upon successful immune-checkpoint blockade2. The
tumor microenvironment presents obstacles to T-cell
infiltration, and there is a growing appreciation for the
metabolic restrictions imposed, such as competition with
tumor cells for glucose3. Thus, it may be advantageous to
couple immune-checkpoint blockade with metabolic
interventions, and to include metabolic robustness in the
engineering of cytotoxic T-cells4. Detailed knowledge of
T-cell metabolism in different contexts would be a pre-
requisite for the rational development of such strategies.
The study of metabolism changed radically with the
ability to do systems-level analyses using mass spectro-
metry5. Currently, there is no consensus regarding how to
prepare non-adherent mammalian cell samples for
metabolomics, and even less guidance specific for
immune cells6,7. Metabolomic studies of human T-cells
have used as many as 30 million cells per replicate8,9, an
input requirement which may prohibit profiling rare T-
cell subsets. A typical extraction protocol for intracellular
metabolites includes: (i) separation of cells from media,
(ii) a wash step to eliminate remaining contaminating
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Nicolaos Jay Palaskas (NPalaskas@mednet.ucla.edu) or
Thomas Glen Graeber (tgraeber@mednet.ucla.edu)
1Division of Hematology and Oncology, Department of Medicine, University of
California Los Angeles, Los Angeles, CA 90095, USA
2Department of Molecular, Cellular, and Integrative Physiology, University of
California Los Angeles, Los Angeles, CA 90095, USA
Full list of author information is available at the end of the article.
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
media metabolites, (iii) quenching of metabolism and
extraction of metabolites. Separation and washing can be
done rapidly with adherent cells, but centrifugation
requires prolonged exposure to the wash solution, which
ideally should maintain physiological conditions while
minimizing post-harvesting metabolic activity.
The purpose of this study was to broadly profile meta-
bolic changes in human T-cells effected by PD-1 axis
signaling using mass spectrometry-based metabolomics
analyzing a panel of 155 polar and semi-polar metabolites.
We simulated in vitro a tumor-directed attack by primed
T-cells and used recombinant human PD-L1 protein to
Fig. 1 (See legend on next page.)
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engage the immune-checkpoint, without the use of target
cells and ensuing issues of cell separation and con-
taminating metabolites. To ensure profiling physiological-
range conditions, antibody-based activation was adjusted
using melanoma cell line antigen presentation as a guide.
Our approach to minimize input requirements and opti-
mize readout included screening several candidate wash
solutions. As a reference control, we tested the ability of
our assay parameters to identify expected metabolic
changes induced by substitution of glucose by galactose in
culture media. Finally, we incorporated [U-13C] glucose
tracer experiments and analyzed carbon fate by steady-
state isotopomer distributions of metabolites to infer
relative pathway activities. This is particularly useful for
non-linear pathways with multiple possible contributing
pathways, such as the tricarboxylic acid (TCA) cycle10.
Results
Simulating an abortive T-cell tumor-directed attack
To simulate an abortive T-cell tumor-directed attack,
we used stimulating antibodies, followed by recombinant
human PD-L1 exposure in a plate-based system. Pre-
viously frozen PBMC were thawed and expanded for
7 days with induction of surface PD-1 (Supplementary Fig.
S1) before T-cell isolation and treatment (Fig. 1a). Multi-
parameter immuno-phenotyping of T-cell differentiation
using this expansion protocol was previously published by
our group11. We adjusted our treatment conditions to
have the same cytokine-based output levels as a cell-based
antigen presentation system. MART-1-specific transgenic
human T-cells (F5 TCR) were co-cultured with peptide-
presenting target cells and interferon gamma (IFNγ)
release was used to gauge activation and inhibition. As
expected, M202 melanoma and K562-A2.1 peptide-pulsed
cells caused IFNγ release, contrary to mock-pulsed cells
and M238 melanoma cells that do not present the peptide
(Fig. 1b). At a similar level of activation using stimulating
antibodies, the PD-L1 peptide efficiently inhibited IFNγ
release (Fig. 1b).
Optimization of metabolite collection and analysis
Next, we sought to find an appropriate wash solution
for our intracellular metabolite extraction protocol. We
reasoned that microscopy could provide a quick screen
for drastic morphologic changes. Ammonium acetate, a
common metabolite collection-protocol wash solution for
adherent cells, caused Jurkat cells to swell over 4 min,
while a methanol-based solution altered morphology on
contact (Fig. 1c). To more formally assess the effect of
ammonium acetate, we used adherent mouse embryonic
fibroblasts (MEF) cells, because their exposure time to
NaCl 0.9% (isotonic) and ammonium acetate solutions
could be easily controlled. The variability of measure-
ments with ammonium acetate increased as a function of
exposure length (Fig. 1d). To overcome the osmotic
swelling, we chose to proceed with an isotonic solution.
Metabolite profiles of Jurkat cells using NaCl vs. mannitol
isotonic wash solutions were highly correlated, with R2=
0.93 (Fig. 1e), and with mannitol preserving the mea-
surement of more metabolites. To co-optimize for a low
cellular input amount that can quantitatively detect a
substantial number of metabolites, we first assessed the
ability of serial two-fold dilutions to predict the metabo-
lite levels of the maximum cell number sample and found
a good albeit decreasing correlation across the range of
dilutions (Fig. 1f). Nonetheless, the number of repro-
ducibly measured metabolite levels was highest at 5 × 105
cells, although at the cost of detecting fewer metabolites.
Further, our ability to confidently measure decreasing
levels of metabolites of successive dilutions was best
(see figure on previous page)
Fig. 1 Development of a platform to interrogate PD-L1-induced changes by LC/MS metabolomics. a Schematic representation of T-cell
treatment prior to metabolite extraction. PBMC are expanded using a clinical grade adoptive cell transfer protocol that leads to upregulation of PD-1
receptor on the surface of T-cells. Isolated T-cells are then seeded in plates with anti-CD3 and anti-CD28 antibodies with or without recombinant
human PD-L1 (rhPD-L1). b IFN gamma ELISA of 24 h supernatants. T-cells bearing an exogenously expressed MART-1-specific T-cell receptor (F5 TCR)
were co-cultured with M202 melanoma cells that present MART-1 via HLA-A2.1, M238 cells that do not, K562 cells with exogenous expression of HLA-
A2.1 pulsed with MART-126–35 peptide, or stimulated with anti-CD3 and anti-CD28 antibodies without target cells. Anti-CD3 and anti-CD28 antibody-
based activation of T cells is comparable to levels of cell-based melanoma antigen presentation. c Light microscopy images show changes in cellular
morphology with certain wash solutions. Jurkat cells were exposed for the indicated time intervals. The ammonium acetate iso-osmotic wash buffer
provides little tonicity and causes considerable swelling of the cells. The ice-cold ammonium bicarbonate solution in 60% methanol causes cell
changes on contact. In contrast, such changes are not noted with the mannitol solution. d Principal component analysis of 137 of 155 profiled
metabolites demonstrates that the variance of intracellular metabolite measurements increases as a function of time when exposed to the
ammonium acetate solution. Spontaneously immortalized 3T3 mouse embryonic fibroblasts were exposed to a 0.9% NaCl or 150 mM ammonium
acetate solutions for the indicated times. The ellipses were added for emphasis. e Correlation of profiled metabolites between mannitol and NaCl
wash solutions. Triplicates of 2 × 106 Jurkat cells per condition. f Correlation of metabolite measurements of two-fold serially diluted samples. Values
are corrected for the dilution factor. The dashed lines represent a perfect correlation. The solid colored lines are the best fit lines of the data.
g Schematic model displaying the reduced flux of galactose metabolism ending with complete oxidation to CO2 compared to high glycolytic flux
with glucose and production of lactate. h Supernatant lactate levels of activated primary human T-cells in glucose-containing or galactose-containing
culture medium. Displayed are the summary results of three experiments, sampled from three replicate wells per condition (n= 9 vs. 9)
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between 1 × 106 and 5 × 105 cellular inputs (Supplemen-
tary Fig. S2). Based on these comparisons, together with
format considerations, we proceeded with 8.4 × 105 cells
per replicate, using a mannitol wash solution.
To test our parameters for metabolic extraction in the
context of measuring a metabolic change, we activated T-
cells in galactose-containing medium, which is known to
decrease glycolytic flux and force cells to respire (Fig. 1g)12.
As anticipated, lactate production was suppressed in
galactose-containing medium (Fig. 1h). After 24 h, we
detected higher intracellular levels of Leloir pathway
intermediates UDP-hexose and hexose-phosphate with
galactose treatment (Table 1). Aspartic acid was also
elevated, consistent with recent reports of respiration
driving aspartate production in proliferating cells13,14.
Glycolytic intermediates were higher in the glucose con-
dition, as was UDP N-acetylglucosamine, a reflection of
glucose availability for the hexosamine pathway15. These
findings fit expectations based on the literature.
Profiling of PD-L1 checkpoint-induced metabolic changes
reveals a block in de novo nucleoside phosphate synthesis
Next, we interrogated metabolic changes caused in
primary human T-cells by PD1 axis signaling. After 72 h
of treatment, we adequately measured 146 of 155 intra-
cellular metabolites of our panel, and found most to be
reduced by treatment (Fig. 2a). Intracellular levels of
glycolytic intermediates were reduced (Fig. 2b), as were
lactate levels in media (Fig. 2c). Consumption of gluta-
mine and serine were also reduced (Fig. 2c). Relative levels
of nucleoside phosphates were decreased (Fig. 2d).
To probe further, we performed isotopomer analysis.
This showed that despite similar incorporation of heavy
carbons from [U-13C] glucose into ribose, very little label
was incorporated into nucleoside phosphates with PD-L1
treatment (Fig. 3a and Supplementary Fig. S3). Iso-
topomer analysis further showed differential carbon
labeling of Krebs cycle intermediates (Fig. 3b and Sup-
plementary Fig. S4). Based on these carbon tracing
changes, we inferred a model of fluxes into the cycle. PD-1
signaling results in increased reductive carboxylation of
pyruvate, anaplerosis of the cycle at acetyl-CoA and
succinyl-CoA that could come from fatty acids and
branched chain amino acids, less anaplerosis from gluta-
mine, and less nucleoside synthesis despite higher relative
levels of aspartate (Fig. 3c).
We questioned whether the block in nucleoside phos-
phate synthesis was an early event. At a 24 h time-point,
the landscape of metabolic changes was consistent but
more modest than at 72 h (Supplementary Fig. S5).
Among relative level changes caused by PD-L1 treatment
with an FDR < 0.05, we found reduced ribose-5-P and
UMP, and increased aspartic acid (Fig. 4a). The inhibited
cells incorporated less 13C from ribose-5-P into nucleo-
side phosphates, as reflected in their M5 isotopomers. At
this early timepoint, the fold reduction was larger for
pyrimidines than purines (Fig. 4b). The mechanistic target
of rapamycin complex 1 (mTORC1) has been shown to
regulate nucleoside phosphate synthesis16,17. We probed
phosphorylation sites on downstream targets of
mTORC1, including carbamoyl-phosphate synthetase 2,
aspartate transcarbamylase, and dihydroorotase (CAD),
Table 1 Intracellular metabolite level changes of activated human primary T-cells in culture medium containing glucose
vs. galactose
Compound Fold change glucose vs. galactose p-value FDR Pathway
UDP-hexose −1.42 6.39 × 10−5 7.46 × 10−04 Leloir
Hexose-phosphate −8.98 4.07 × 10−4 3.36 × 10−03 Both
Fructose-1,6-bisphosphate 9.22 8.37 × 10−7 2.34 × 10−05 Glycolysis
Glyceraldehyde-3-P 1437.38 9.12 × 10−4 4.91 × 10−03 Glycolysis
Dihydroxyacetone-P 583.69 6.54 × 10−3 2.41 × 10−02 Glycolysis
3-phosphoglycerate 2.75 4.90 × 10−4 3.61 × 10−03 Glycolysis
Phosphoenolpyruvate 1.24 7.23 × 10−1 8.04 × 10−01 Glycolysis
Pyruvate −1.52 4.44 × 10−1 5.92 × 10−01 Glycolysis
Lactate 44.66 2.41 × 10−6 3.97 × 10−05 Glycolysis
UDP N-acetylglucosamine 16.26 1.46 × 10−6 2.92 × 10−05 Misc
Aspartic acid −5.97 4.76 × 10−4 3.61 × 10−03 Misc
Summary of three experiments with each condition performed in triplicate
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and found decreased mTORC1 activity with PD-L1
treatment (Fig. 4c). In certain cellular contexts, isolated
deficiency of nucleoside phosphate synthesis can be res-
cued by providing exogenous downstream substrates,
including nucleosides16–18. However, in this checkpoint
context, we could not document a rescue of proliferation
in PD-L1-treated cells supplemented with exogenous
nucleosides (Fig. 4d and Supplementary Fig. S6).
Fig. 2 Relative levels of intracellular and supernatant metabolites in activated vs. PD-L1-inhibited T-cells. a Overview of all profiled
intracellular metabolites as measured by mass spectrometry. Positive values indicate higher levels in the treated condition (PD-L1). Dotted lines
represent a two-fold change on the log2 scale. Values are capped at 100-fold. b Intracellular glycolysis pathway intermediates are lower in inhibited
cells. c Compared to Fc control cells, less lactate and alanine are produced, and less glucose, glutamine, and serine are consumed. d Nucleoside
phosphates are reduced and aspartic acid levels are increased by PD-L1. FDR: false discovery rate. †: FDR > 0.05. All values represent four experiments
with triplicates of each condition and have FDR < 0.05 unless indicated otherwise
Fig. 3 [U-13C] glucose tracing shows differences in metabolite contribution to the TCA cycle and decreased de novo nucleoside phosphate
synthesis upon PD-L1 inhibition. a Selected isotopomers of uridine monophosphate and ribose-5-phosphate that represent the contribution of
fully labeled ribose-5-phosphate (UMP M5) plus partially labeled aspartic acid (UMP M6–7). b Selected isotopomers of TCA metabolites used to infer
metabolite contributions to the TCA cycle, expressed as the percentage of all isotopomers detected for the respective compounds. M0: unlabeled.
M2: Two heavy carbons from glucose. M3: Three heavy carbons from glucose. c Schematic of inferred relative contributions to the TCA cycle in PD-
L1-treated cells. Thick arrows represent more relative contribution of metabolites in the PD-L1-treated cells compared to the Fc control
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Inhibition of mTOR partially phenocopies the PD-L1-
mediated block in de novo nucleoside phosphate
synthesis
We questioned whether the block in pyrimidine
nucleoside phosphate synthesis could be solely attributed
to mTORC1 inhibition, or whether additional PD-L1-
activated mechanisms were responsible for the magnitude
of the phenotype and its refractoriness to reversal by
exogenous nucleoside administration. To address this
question we similarly stimulated and expanded T-cells for
7 days and then treated for 48 h with rapamycin, a known
inhibitor of mTORC1 and an immunosuppressant used
clinically19. We found that low doses of rapamycin were
sufficient to block phosphorylation of p-70 S6 kinase and
its target phosphorylation site on CAD, although phos-
phorylation of 4E-BP1 was only reduced at much higher
doses (Fig. 5a and Supplementary Fig. S7). We next
measured intracellular nucleoside phosphate levels and
found lower levels upon rapamycin treatment (Fig. 5b),
yet the effect was smaller than with PD-L1 treatment for
72 h (Fig. 2d). We confirmed that exogenous unlabeled
nucleosides could be incorporated in the intracellular
metabolite pool by measuring the fraction of [U-13C]
glucose-derived label. Glucose-derived heavy carbon
labeling could be competitively depleted by increasing
concentrations of unlabeled nucleosides (Fig. 5c). How-
ever, similarly to the PD-L1 treatment, mTOR inhibition
could not be circumvented by the administration of the
nucleoside cocktail, as measured by the metabolic activity
(resazurin reduction capacity) of the treated T-cells
(Fig. 5d).
Discussion
Our motivation to study human T-cell metabolism led
us to develop an in vitro platform where cells can be
activated and treated with ligands, drugs, or different
nutrient conditions, and metabolic changes can be mea-
sured by LC/MS, with the use of an extraction protocol
optimized for T-cells. This approach enabled us to exhibit
a landscape of metabolic changes caused by PD-1
checkpoint engagement. Our study is unique, in that we
have used a cell-based antigen presentation system as a
guide for relevant in vitro artificial stimulation, and used
[U-13C] glucose, to infer pathway activities and substrate
Fig. 4 PD-L1 causes a block in nucleoside phosphate synthesis at 24 h. a Relative levels of nucleoside phosphates and aspartic acid at 24 h of
treatment. b Statistically significantly changing 13C incorporation into nucleoside phosphates from [U-13C] glucose via ribose-5-P, as reflected in the
their M5 isotopomers. All measurements have a FDR < 0.05 but the fold-reduction is larger for pyrimidines than for purines. c Western blot of
phosphorylation status of mTORC1 targets. T-cells were treated for 48 h as indicated. Jurkat cells were treated for 2 h. PHA: phytohemagglutinin 5 µg/
mL. Rapa: rapamycin 20 nM. d Metabolic activity (alamar blue resazurin reduction) assay of Fc and PD-L1-treated T-cells with or without nucleoside
cocktail supplementation for 48 h. Summary of three experiments performed on separated days in triplicates (n= 9 per condition)
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utilization in PD-L1-treated primary human T-cells. This
strategy allowed us to uncover a PD-L1-induced block in
de novo nucleoside phosphate synthesis, although it
remains an in vitro study of a single signaling pathway and
cannot fully capture the complexities of the tumor
microenvironment.
There are several proposed methods for metabolite
extraction of non-adherent cells. We found isotonic
solutions to be the most appropriate for washing (Fig. 1c, d)
and chose to work with mannitol because it is compatible
with both LC/MS and capillary electrophoresis technol-
ogies20. Early in our investigation we evaluated a filter-
based method originally applied to microbial extraction
that did not require pumps and automation21, but despite
experimenting with several filter types and sizes we found
filter clogging to be an issue. This limitation and reports
of suboptimal recovery of metabolites from filters6 led us
to prioritize a centrifugation-based strategy. A methanol-
based wash solution22 distorted cells on contact (Fig. 1c)
and has been reported to cause leakage of metabolites6,
leading us to consider this option no further. Ammonium
acetate is a common metabolite extraction wash solution
because it is volatile and should not contribute to ion
suppression after evaporation during sample preparation.
A study with primary focus on lipidomics in Jurkat cells
concluded that ammonium acetate is appropriate for
human non-adherent cell metabolomics7. In our work, we
found that it causes cells to swell. Penetration of mam-
malian cells by ammonium salts of weak acids has been
studied23. More importantly, we found metabolite varia-
bility increased as a function of time exposed to ammo-
nium acetate (Fig. 1d). However, we analyzed polar
metabolites and do not know whether the lipid com-
partment is similarly affected.
We found that PD-1 inhibitory signaling shifts meta-
bolism away from aerobic glycolysis and glutaminolysis
(Fig. 2b, c), and forces the cell to utilize alternative sub-
strates to feed the TCA cycle (Fig. 3b, c), in agreement
with previous reports9,24. The single other mass
spectrometry-based metabolomics study related to PD-1
signaling9 reported a block in the uptake and utilization of
branched chain amino acids (BCAA), based on relative
levels of intracellular and extracellular valine, and intra-
cellular levels of the downstream metabolite 4-methyl-2-
oxopentanoate. Induction of carnitine palmitoyltransferase
I expression and increased mitochondrial spare respiratory
capacity were also demonstrated, reminiscent of findings
in murine T-memory cells25. In contrast to T-memory
Fig. 5 Nucleoside supplementation does not circumvent mTOR inhibition. a T-cells were treated with the indicated concentrations of
rapamycin for 48 h and levels of mTORC1 phosphorylation targets were assayed by western blot. b Rapamycin treatment reduces relative intracellular
levels of nucleoside phosphates. Summary of two experiments run in triplicates (n= 6, 6) assayed at a 48 h time-point. c Supplementation of
unlabeled nucleosides results in a decrease of glucose-derived heavy carbon label incorporation into nucleoside phosphates at 48 h. Results of two
experiments with all conditions run in triplicate. d Metabolic activity (alamar blue resazurin reduction) assay of T-cells treated with 20 nM rapamycin
for 48 h and additionally treated with the indicated concentrations of nucleoside cocktail
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cells, lysosomal acid lipase (LAL) was not increased while
adipose triglyceride lyase (ATGL) protein levels were.
ATGL appears dispensable for T-cell memory25. We
showed that unlabeled carbons enter the TCA cycle as
acetyl-CoA (Fig. 3c), which does not support the idea of
PD-L1-treated cells engaging in “cell-intrinsic lipolysis”.
This term refers to the futile diversion of glucose-derived
carbon into triglyceride synthesis by T-memory cells, only
to be mobilized from lysosomes to re-enter the TCA
cycle25. Thus, fatty acid beta-oxidation appears qualita-
tively different between PD-1-signaling cells and T-
memory cells. Future studies are required to elucidate
whether these early metabolic differences between PD-1-
signaling cells and T-memory cells are causally linked to
their distinct epigenetic profiles and potential for reinvi-
goration26,27. Considering the block of BCAA catabolism
reported with PD-1 signaling9, the increase of unlabeled
carbons we documented entering the TCA cycle at
succinyl-CoA (Fig. 3c) must be attributed to the terminal
three carbons of odd-chain fatty acids alone. However, our
study does not provide the fractional contribution of each
substrate to definitively confirm a block in BCAA cata-
bolism, nor can we discount effects that our different
treatment conditions could have had on those fractions.
For the first time, we demonstrated that PD-1 signaling
results in a block of nucleoside phosphate de novo
synthesis. This was more notable for pyrimidines at an
early, 24 h timepoint (Fig. 4b). The difference in timing is
consistent with pyrimidine de novo synthesis being con-
trolled rapidly by mTORC1 phosphorylation of CAD and
the control of purine synthesis being regulated through
slower transcriptional mechanisms16,17. Indeed, we
observed less phosphorylation of canonical mTORC1
targets and CAD (Fig. 4c). Activated T-lymphocytes are
dependent on de novo purine and pyrimidine synthesis
for proliferation and survival, and nucleotides regulate
their cell cycle28. Nonetheless, a cocktail of purines and
pyrimidines by itself was not sufficient to rescue the
proliferation of PD-L1-treated cells (Fig. 4d). Additionally,
mTOR inhibition by rapamycin treatment only partially
phenocopied the block in nucleoside phosphate de novo
synthesis and incorporation of glucose-derived heavy
carbons, even though the phosphorylation of CAD and p-
70 S6K was effectively inhibited (Fig. 5a). On the one
hand, this suggests that S6K activity is not the only
determinant of de novo pyrimidine and purine synthesis,
although required for full capacity. Rapamycin-resistant
T-cell proliferation has been documented in the context
of strong T-cell receptor stimulation19, which would
require such residual ability to synthesize RNA and DNA
building blocks. On the other hand, even the partial
inhibition by rapamycin was not circumventable by the
provision of exogenous nucleosides. In fact, this inter-
vention appeared to be further deleterious to the meta-
bolic fitness of the cells (Fig. 5d). Possibly, this is an
indication of substrate level negative feedback29. While we
did not identify an effective maneuver to clearly define the
role of mTOR in the context of PD-L1 signaling, con-
ceivably there may be a combination of individual
nucleoside concentrations that would have a positive
effect. Based on the more profound inhibition with PD-L1
compared to rapamycin it is tempting to invoke other
nodes of metabolic regulation, in addition to the central
role and multiple functions described for mTOR in T-cell
biology30. PD-1 signaling also inhibits AKT, another
central regulator of proliferation and metabolism24. Fur-
thermore, PD-1 inhibits the cell cycle through upregula-
tion of p27kip1, in contrast to the PI3K-dependent
downregulation of p27kip1 described in rapamycin-
resistant T-cell proliferation19,31.
Future in vivo studies with transgenic animals will likely
be required to expand on our findings and define which
metabolic interventions can be coupled with immu-
notherapies for increased therapeutic efficacy.
Materials and methods
Cell lines and culture
Peripheral blood mononuclear cells (PBMCs) were
obtained from a healthy donor by leukapheresis under
UCLA IRB#10-001598. M202 and M238 were established
from patient biopsies with informed consent from all
subjects under UCLA institutional review board approval
IRB#02-08-06732. The K562-A2.1 cell line was a kind gift
of Dr. Cedric Britten33. Human PBMCs, Jurkat cells,
M202 and M238 melanoma cells were cultured in RPMI
1640 with glutamine and supplemented with 10% fetal calf
serum (FCS) and 1% streptomycin, penicillin, and fungi-
some antibiotic cocktail (100x SPF, 10,000 units/mL
penicillin, 10,000 µg/mL of streptomycin, and 25 µg/mL
Amphotericin B). Immortalized MEF were cultured in
DMEM with 10% FCS and 1% SPF. MEFs were immor-
talized as previously described34.
T-cell-directed expansion of PBMCs
Human PBMCs were expanded toward the T-cell line-
age as previously described11 using 10% FCS instead of
human AB serum. Medium acidity was monitored and
fresh medium added every 2 days to maintain a con-
centration of 7 × 105 cells/mL.
T-cell activation and treatment with PD-L1
Twelve-well non-tissue culture-treated plates (Corning
#351143) were coated at 4 °C overnight with 1 µg/mL
anti-CD3 antibody (BD biosciences 555329) and 1.5 µM
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human IgG Fc fragment (Jackson Immunoresearch #009-
000-008) or 1.5 µM recombinant human Fc-tagged PD-L1
(rhPD-L1.Fc) (Sino Biological #10084-H02H) in 1.2 mL
PBS per well. The plate was washed twice with 2 mL PBS
and blocked for 1 h at room temperature with 1.5 mL
human serum albumin 2.5% in phosphate-buffered solu-
tion (PBS), followed by two more washes with PBS. T-cells
previously expanded for 7 days were isolated by immu-
nomagnetic negative enrichment kit (ThermoFisher
#11344D) and seeded in triplicate wells at 8.4 × 105cells in
1.2 mL glucose-free RPMI (ThermoFisher #11879020)
supplemented with 10 mM [U-13C] glucose (Cambridge
Isotope Laboratories #CLM-1396-PK), 10% dialyzed fetal
calf serum, 1% SPF, and 1 µg/mL anti-CD28 antibody (BD
biosciences #555725). For 72-h treatments, the treatment
medium was refreshed 24 h prior to harvest.
T-cell metabolite extraction protocol
Treated T-cells were harvested into microcentrifuge
tubes and centrifuged at 500×G-force for 4 min. The
medium was collected and stored at −80 °C until further
processing. Ice-cold 5.4% mannitol wash solution was
added, 1 mL to each pellet, and centrifuged with the same
parameters at 4 °C. Subsequent steps were performed on
ice with solutions ice-cold. The wash solution was
removed and sequentially 250 µL methanol, 250 µL water,
and finally 250 µL chloroform were added, vortexing
briefly between steps. The mixture was centrifuged at
16,000×G-force for 5 min. The top polar phase was col-
lected into glass chromatography vials and stored at
−80 °C until further processing. Interphase protein was
measured by BCA assay kit (ThermoFisher #23225). The
polar phase, 20 µL of the supernatants, and three mock-
extracted controls per run (polar phase of extraction
mixture without cells) were evaporated with an EZ2-Elite
centrifugal evaporator for 80min on HPLC setting with
30 °C maximum temperature. The samples were block-
randomized and stored at −80 °C prior to recovery and
submission of 1/10 of each replicate for mass spectro-
metry. Additional extraction methods tested are described
in the supplemental methods.
Co-culture of transgenic T-cells with melanoma and K562
targets
Transgenic MART-1-specific TCR-bearing T-cells (F5
cells) were co-cultured at 1:1 effector to target ratio for
24 h with melanoma, or either pulsed (MART-126–35) or
non-pulsed K562-A2.1 cells in 24-well plates with 1 × 106
cells in 1 mL as previously described35. IFNγ release was
assayed by ELISA (ThermoFisher #88-7316-77).
Western blotting
Primary antibodies used were Phospho-CAD (Ser1859)
Antibody #12662, Phospho-p70 S6 Kinase (Thr389)
(108D2) Rabbit mAb #9234, Phospho-4E-BP1 (Ser65)
(174A9) Rabbit mAb #9456, and β-Actin (D6A8) Rabbit
mAb #8457 from Cell Signaling.
Data analysis
Mass spectrometry metabolomics data were mean-
normalized between runs. Significant changes were cal-
culated using a two-sided Student’s t-test assuming
unequal variance. P-values were adjusted for multiple
hypothesis testing using Benjamini and Hochberg’s
method of false discovery rate (FDR). Analysis was per-
formed in R36.
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